Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Merck and Moderna Report Success Merck and Moderna reported on August 19 the results of the INTerpath-001 phase III study with 1,137 participants. After complete removal of high-risk melanoma, all participants received pembrolizumab: one group was also given a personally tailored intismeran, while the other received a placebo. The companies reported that the combination achieved two study goals: time without recurrence and time without distant metastases. After melanoma removal, the risk of its return remains. Pembrolizumab is an immunotherapy that blocks the PD-1 protein, which reduces the activity of T-cells that can attack tumors. Intismeran gives these cells specific targets. According to oncologist Lennard Lee, as quoted in the Science Media Centre, the combination of the two drugs works by "one helping the immune system understand what to look for, and the other taking the brakes off the immune response". For intismeran, a tumor sample from a specific patient is taken, and up to 34 neoantigens - fragments of proteins that distinguish cancer cells from healthy ones - are selected. Their sequences are recorded in mRNA: after injection, the patient's cells produce these fragments and show them to T-cells. 🔗 Read original →